Date: 2011-03-17
Type of information: Licensing agreement
Compound: biomarker gene expression profiling and immunohistochemistry technologies
Company: Epistem (UK) Sanofi-Aventis (France)
Therapeutic area:
Type agreement: R&D licensing
Action mechanism:
Disease:
Details: Epistem has announced a collaboration with sanofi-aventis U.S. Inc. relating to the use of Epistem's proprietary biomarker gene expression profiling and immunohistochemistry technologies. Under the terms of the agreement Sanofi-Aventis has entered into a 3 year collaboration with Epistem to provide discovery through to clinical biomarker support to oncology programmes of sanofi-aventis and its affiliates. The collaboration is expected to inform Sanofi-Aventis Oncology programmes with a biomarker strategy aimed at identifying biological responses to drugs in relevant tissues. The translational nature of this relationship means activities will cover preclinical, ex vivo and clinical support.
Financial terms:
Latest news:
